Panel Discussion: Expanding the Druggable Universe & the Future of Rational Drug Design in an Era of AI, Structural Biology & Emerging Modalities

• Explore why complex, dynamic, and previously inaccessible targets have challenged traditional drug discovery approaches
• Discover how advances in structural biology, biophysics, computational chemistry, and AI are expanding the druggable proteome
• Understand how molecular glues, degraders, and other emerging modalities reshaping discovery portfolios are and required capabilities
• Identify which technologies are driving value today versus those likely to transform discovery over the next decade
• Learn how leading organisations are combining experimental and computational approaches to pursue challenging targets with greater confidence

Speakers:

David Brown

Senior Director Structural Biology and Biophysics

Vertex Pharmaceuticals

Kirill Pevzner

Founder & Chief Technical Officer

Protai

Jonathan Hopper

Founder & Vice President - Platforms

OMass Therapeutics

Ilaria Ferlenghi

Associate Director, Senior Scientific Leader Protein Structure & Biochemistry, Vx Discovery Tech

GSK

Alexey Rak

Head of Bio Structure & Biophysics

Sanofi